<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00623623</url>
  </required_header>
  <id_info>
    <org_study_id>1123.28</org_study_id>
    <secondary_id>2007-001219-44</secondary_id>
    <nct_id>NCT00623623</nct_id>
  </id_info>
  <brief_title>STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction</brief_title>
  <official_title>STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within 6-24 Hours or Rescue Coronary Intervention Versus a Strategy of Standard Primary PCI in Patients With Acute Myocardial Infarction Within 3 Hours of Onset of Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This study aims at evaluating, in a proof of concept approach, the outcome of patients
      presenting with acute ST-elevation myocardial infarction within 3 hours of symptom onset in
      either a pre-hospital setting or community hospital emergency room without a PCI facility.
      Following randomisation a strategy of early tenecteplase and additional antiplatelet and
      antithrombin therapy followed by catheterisation within 6-24 hours with timely coronary
      intervention as appropriate (or by rescue coronary intervention if required) in Group A will
      be compared to primary PCI performed according to local standards in Group B.

      The study is exploratory in nature and will examine this medical question. The efficacy and
      safety endpoints as well as mixed (efficacy and safety) composite endpoints up to or before
      30 days following randomisation will be evaluated.

      All clinical endpoints of main interest will be assessed as single or composite endpoints for
      evaluation of the trial objective. All statistical tests are of exploratory nature based on
      descriptive p-values for formal statistical hypotheses generation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2008</start_date>
  <completion_date type="Actual">September 1, 2012</completion_date>
  <primary_completion_date type="Actual">September 1, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.</measure>
    <time_frame>30 days</time_frame>
    <description>The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With All Cause Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Cardiac Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Cardiogenic Shock</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Congestive Heart Failure (CHF)</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Recurrent Myocardial Infarction (Reinfarction)</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Rehospitalisation for Cardiac Reasons</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Rehospitalisation for Non-cardiac Reasons</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Serious Repeat Target Vessel Revascularization</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With All Cause Death and Shock</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With All Cause Death and Shock and CHF</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With All Cause Death and Shock and Reinfarction</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Total Fatal Stroke</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Total Disabling Stroke</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Total Non-disabling Stroke</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Intracranial Haemorrhage</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Ischaemic Stroke</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Total Stroke (All Types)</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Minor Non-intracranial Bleeds</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Total Non-intracranial Bleeds</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Serious Resuscitated Ventricular Fibrillation</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Serious Resuscitated Ventricular Fibrillation in Association With Invasive Procedures</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With All Cause Death and Non-fatal Stroke</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke</measure>
    <time_frame>30 days</time_frame>
    <description>This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1899</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Tenecteplase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early tenecteplase, clopidogrel and enoxaparin followed by routine or rescue coronary intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>primary PCI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard primary PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>primary PCI</intervention_name>
    <description>Standard primary PCI</description>
    <arm_group_label>primary PCI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enoxaparin</intervention_name>
    <description>Adjunctive treatment</description>
    <arm_group_label>Tenecteplase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>catheterisation</intervention_name>
    <description>Routine or rescue coronary intervention</description>
    <arm_group_label>Tenecteplase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenecteplase</intervention_name>
    <description>Single, weight-adjusted i.v. bolus of tenecteplase</description>
    <arm_group_label>Tenecteplase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>Adjunctive treatment</description>
    <arm_group_label>Tenecteplase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Age equal or greater than 18 years

          2. Onset of symptoms &lt; 3 hours prior to randomisation 3.12-lead ECG indicative of an
             acute STEMI

        4.Informed consent received

        Exclusion criteria:

        Medical history, procedures, medication administration or the presence of factors that
        would in general predispose to bleeding events and/or the inability to evaluate the study
        primary endpoint
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1123.28.43009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.43010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.43002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.43003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.43004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.43005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.43007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.43008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.32060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bornem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.32010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.32070 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Herentals</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.32040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.55010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brasilia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.55020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brasilia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.55008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cabo Frio</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.55017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.55007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.55001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Recife</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.55018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.55028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.55016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sao Lourenço do Sul</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.55004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.55014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.11006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.11505 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.11002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.13001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.13002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.13003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.13004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.13005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.13006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3376A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ambérieu en Bugey</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3329A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aubervilliers Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3329B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aubervilliers Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3329C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aubervilliers Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3351A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3351B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3315A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Besançon cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3315B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Besançon cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3302B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3319A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3319B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3319C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3374A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bourg en Bresse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3385A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bourg en Bresse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3383A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bourg-en-Bresse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3347A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bourges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3347B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bourges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3347C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bourges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3355A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3355B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3382A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Caluire et Cuire</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3311A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Châteauroux cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3311B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Châteauroux cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3346A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Châteauroux cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3346B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Châteauroux cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clichy Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3309A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dreux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3342A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dreux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3337A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Evecquemont</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3387A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort De France Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3388A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort De France Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3353A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3353B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3317A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Tronche</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3317B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Tronche</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3339A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Le Chesnay Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3339B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Le Chesnay Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3307A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Le Chesnay</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3336A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Le Port-Marly</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3301B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3325A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3325B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3326A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3318A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lyon cedex 3</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3318B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lyon cedex 3</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3318C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lyon cedex 3</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3369A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lyon cedex 4</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3369B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lyon cedex 4</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3356A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lyon cedex 7</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3356B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lyon cedex 7</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3308A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Melun cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3308B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Melun cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3340A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Melun</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3340B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Melun</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3379A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montelimar Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3328A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montfermeil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3328B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montfermeil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3328C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montfermeil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3349A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3349B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3313A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3313B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3322A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nice cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3322B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nice cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3322C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nice cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3366A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nice cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3375A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oyonnax</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3334A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris cedex 10</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3331A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3371A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3357A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3338A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poissy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3316A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pringy Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3352A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pringy Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3341A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quincy-sous-Senart</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3378A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Romans sur Isère</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3310A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rouen cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3310B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rouen cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3344A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rouen Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3345A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3345B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3345C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3377A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valence Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3384A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valence Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.3373A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vienne Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.49012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Duisburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.49052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankenthal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.49026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sömmerda</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.30012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alexandroupolis</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.30001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.30003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chalikida</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.30011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Katerini</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.30014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kavala</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.30006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Korinthos</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.30002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leivadia</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.30007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.30010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.30005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thiva</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.30009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Veroia</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.39201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.39002A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.39022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.39004A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Imperia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.39200A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lagosanto (FE)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.39001A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.39011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.39082 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pescia (Pistoia)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.39083 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pescia (Pistoia)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.39008A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pistoia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.39081 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pistoia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.39041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sanremo (IM)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.47005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamar</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.47001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.47002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.19001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.19004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.48002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gniezno</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.48006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gniezno</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.48009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grodzisk Wielopolski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.48001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.70005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.77005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.70001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.77001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.70009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Irkutsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.77009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Irkutsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.70002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.77002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.70008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Murmansk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.77008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Murmansk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.77003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.70003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nizhnyi Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.70006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.70007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.77006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.70004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.77004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.38101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.38103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.38104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.38106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.38107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.38109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sabac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.38108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Smederevo</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.38110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vrsac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.38111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zajecar</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.38104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zemun</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.38105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zemun</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Almeria</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.34003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huelva</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.34007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.34011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.44600 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.44610 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.44210 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.44220 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.44200 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chippenham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.44620 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dundonald</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.44110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.44630 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1123.28.44100 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 15, 2008</study_first_submitted>
  <study_first_submitted_qc>February 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2008</study_first_posted>
  <results_first_submitted>June 6, 2019</results_first_submitted>
  <results_first_submitted_qc>June 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 1, 2019</results_first_posted>
  <disposition_first_submitted>April 30, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>April 30, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 16, 2014</disposition_first_posted>
  <last_update_submitted>June 6, 2019</last_update_submitted>
  <last_update_submitted_qc>June 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Tenecteplase</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Open-label, prospective, randomised, parallel, comparative international multicentre trial</recruitment_details>
      <pre_assignment_details>All subjects were screened for eligibility to participate in trial. Subjects attended specialist sites to ensure that they (the subjects) met all implemented inclusion/exclusion criteria. Subjects were not to be randomised to trial drug if any of the specific entry criteria was violated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tenecteplase (Group A)</title>
          <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
        </group>
        <group group_id="P2">
          <title>Primary PCI (Group B)</title>
          <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="950"/>
                <participants group_id="P2" count="949"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="949"/>
                <participants group_id="P2" count="948"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Previous enrolment into this study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS): All consented patients either randomised by Interactive Voice Response System (IVRS) or treated (i.e., manually allocated to treatment group) by the investigator. This population is also referred to as the intention-to-treat population (ITT).</population>
      <group_list>
        <group group_id="B1">
          <title>Tenecteplase (Group A)</title>
          <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
        </group>
        <group group_id="B2">
          <title>Primary PCI (Group B)</title>
          <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="949"/>
            <count group_id="B2" value="948"/>
            <count group_id="B3" value="1897"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>FAS</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="949"/>
                    <count group_id="B2" value="948"/>
                    <count group_id="B3" value="1897"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="12.42"/>
                    <measurement group_id="B2" value="60" spread="12.49"/>
                    <measurement group_id="B3" value="60" spread="12.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="949"/>
                    <count group_id="B2" value="948"/>
                    <count group_id="B3" value="1897"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="208"/>
                    <measurement group_id="B3" value="403"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="754"/>
                    <measurement group_id="B2" value="740"/>
                    <measurement group_id="B3" value="1494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.</title>
        <description>The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS).</description>
        <time_frame>30 days</time_frame>
        <population>Full analysis set (FAS): All consented patients either randomised by Interactive Voice Response System (IVRS) or treated (i.e., manually allocated to treatment group) by the investigator. This population is also referred to as the intention-to-treat population (ITT).</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.</title>
          <description>The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS).</description>
          <population>Full analysis set (FAS): All consented patients either randomised by Interactive Voice Response System (IVRS) or treated (i.e., manually allocated to treatment group) by the investigator. This population is also referred to as the intention-to-treat population (ITT).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.195</p_value>
            <method>modified Poisson regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative risk</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With All Cause Mortality</title>
        <description>This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported.</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With All Cause Mortality</title>
          <description>This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.904</p_value>
            <method>modified Poisson regression</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative risk</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Cardiac Mortality</title>
        <description>This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported.</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Cardiac Mortality</title>
          <description>This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.905</p_value>
            <method>modified Poisson regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative risk</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Cardiogenic Shock</title>
        <description>This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported.</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Cardiogenic Shock</title>
          <description>This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.120</p_value>
            <method>modified Poisson regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative risk</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Congestive Heart Failure (CHF)</title>
        <description>This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported.</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Congestive Heart Failure (CHF)</title>
          <description>This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.170</p_value>
            <method>modified Poisson regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative risk</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Recurrent Myocardial Infarction (Reinfarction)</title>
        <description>This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Recurrent Myocardial Infarction (Reinfarction)</title>
          <description>This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.758</p_value>
            <method>modified Poisson regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative risk</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Rehospitalisation for Cardiac Reasons</title>
        <description>This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Rehospitalisation for Cardiac Reasons</title>
          <description>This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.663</p_value>
            <method>modified Poisson regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative risk</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Rehospitalisation for Non-cardiac Reasons</title>
        <description>This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Rehospitalisation for Non-cardiac Reasons</title>
          <description>This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.148</p_value>
            <method>modified Poisson regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative risk</param_type>
            <param_value>1.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>3.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Serious Repeat Target Vessel Revascularization</title>
        <description>This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serious Repeat Target Vessel Revascularization</title>
          <description>This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.572</p_value>
            <method>modified Poisson regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative risk</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>5.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With All Cause Death and Shock</title>
        <description>This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With All Cause Death and Shock</title>
          <description>This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.207</p_value>
            <method>modified Poission Regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative risk</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With All Cause Death and Shock and CHF</title>
        <description>This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported.</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With All Cause Death and Shock and CHF</title>
          <description>This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.100</p_value>
            <method>modified Poission Regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative risk</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With All Cause Death and Shock and Reinfarction</title>
        <description>This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With All Cause Death and Shock and Reinfarction</title>
          <description>This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.511</p_value>
            <method>modified Poission Regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative Risk</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Total Fatal Stroke</title>
        <description>This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Total Fatal Stroke</title>
          <description>This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.369</p_value>
            <method>modified Poisson regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative Risk</param_type>
            <param_value>1.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>5.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Total Disabling Stroke</title>
        <description>This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Total Disabling Stroke</title>
          <description>This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.168</p_value>
            <method>modified Poisson regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative Risk</param_type>
            <param_value>4.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>49.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Total Non-disabling Stroke</title>
        <description>This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Total Non-disabling Stroke</title>
          <description>This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.049</p_value>
            <method>modified Poisson regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative Risk</param_type>
            <param_value>8.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>63.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Intracranial Haemorrhage</title>
        <description>This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Intracranial Haemorrhage</title>
          <description>This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.054</p_value>
            <method>modified Poisson regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative Risk</param_type>
            <param_value>4.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>20.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Ischaemic Stroke</title>
        <description>This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Ischaemic Stroke</title>
          <description>This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.324</p_value>
            <method>modified Poisson regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative Risk</param_type>
            <param_value>2.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>7.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Total Stroke (All Types)</title>
        <description>This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Total Stroke (All Types)</title>
          <description>This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>modified Poisson regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative Risk</param_type>
            <param_value>3.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>8.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions</title>
        <description>This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions</title>
          <description>This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.111</p_value>
            <method>modified Poisson regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative Risk</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Minor Non-intracranial Bleeds</title>
        <description>This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Minor Non-intracranial Bleeds</title>
          <description>This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.397</p_value>
            <method>modified Poisson regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative Risk</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Total Non-intracranial Bleeds</title>
        <description>This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Total Non-intracranial Bleeds</title>
          <description>This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267"/>
                    <measurement group_id="O2" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.107</p_value>
            <method>modified Poisson regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative Risk</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Serious Resuscitated Ventricular Fibrillation</title>
        <description>This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serious Resuscitated Ventricular Fibrillation</title>
          <description>This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.471</p_value>
            <method>modified Poisson regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative Risk</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Serious Resuscitated Ventricular Fibrillation in Association With Invasive Procedures</title>
        <description>This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serious Resuscitated Ventricular Fibrillation in Association With Invasive Procedures</title>
          <description>This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No confirmatory statistical hypothesis was pre-specified. All statistical tests were of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>modified Poisson regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative Risk</param_type>
            <param_value>0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With All Cause Death and Non-fatal Stroke</title>
        <description>This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With All Cause Death and Non-fatal Stroke</title>
          <description>This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.451</p_value>
            <method>modified Poisson regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative risk</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke</title>
        <description>This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported</description>
        <time_frame>30 days</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tenecteplase (Group A)</title>
            <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
          </group>
          <group group_id="O2">
            <title>Primary PCI (Group B)</title>
            <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke</title>
          <description>This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="948"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.220</p_value>
            <method>modified Poisson regression model</method>
            <method_desc>modified Poisson regression model with robust error variance</method_desc>
            <param_type>Relative Risk</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until end of tiral, up to 30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tenecteplase (Group A)</title>
          <description>Patients were administered Tenecteplase in a weight-adjusted dose regimen with clopidogrel (concomitant antiplatelet) and Enoxaparin (anticoagulant treatment) followed by timely coronary intervention (pharmacoinvasive treatment)</description>
        </group>
        <group group_id="E2">
          <title>Primary PCI (Group B)</title>
          <description>Patients received primary Percutaneous Coronary Intervention (PCI) according to local standards.
Preceding and concomitant medication in particular antiplatelet and antithrombin drugs were to be given according to local standards and international guidelines.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="164" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated idioventricular rhythm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Coronary artery perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Myocardial rupture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Parasystole</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Postinfarction angina</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Torsade de pointes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hepatitis cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Sputum purulent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Toxic shock syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Fat embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Blood electrolytes abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST segment elevation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pulse absent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Red blood cell sedimentation rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Myeloproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Renal cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Neuromyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Coronary revascularisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Mechanical ventilation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Resuscitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="949"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

